Veena Venugopalan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6904892/publications.pdf

Version: 2024-02-01

27 305
papers citations h-i

9 17
h-index g-index

27 27 all docs citations

27 times ranked 419 citing authors

#	Article	IF	CITATIONS
1	Early therapeutic monitoring of \hat{l}^2 -lactams and associated therapy outcomes in critically ill patients. Journal of Antimicrobial Chemotherapy, 2020, 75, 3644-3651.	3.0	44
2	Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections. Open Forum Infectious Diseases, 2020, 7, ofaa051.	0.9	36
3	Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i> . Open Forum Infectious Diseases, 2021, 8, ofab371.	0.9	36
4	Clinical and Microbiologic Outcomes in Patients with Monomicrobial Stenotrophomonas maltophilia Infections. Antimicrobial Agents and Chemotherapy, $2019, 63, \ldots$	3.2	28
5	Administration of a survey to evaluate the attitudes of house staff physicians towards antimicrobial resistance and the antimicrobial stewardship programme at a community teaching hospital. Journal of Global Antimicrobial Resistance, 2016, 4, 21-27.	2.2	25
6	Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	25
7	An Update on Existing and Emerging Data for Meropenem-Vaborbactam. Clinical Therapeutics, 2020, 42, 692-702.	2.5	17
8	Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms. International Journal of Antimicrobial Agents, 2018, 52, 719-723.	2.5	13
9	Management of skin and soft-tissue infections at a community teaching hospital using a severity-of-illness tool. Journal of Antimicrobial Chemotherapy, 2016, 71, 3268-3275.	3.0	12
10	Preparing Students to Enter the Race for Postgraduate Training. Journal of Pharmacy Practice, 2017, 30, 476-482.	1.0	10
11	Impact of an antimicrobial stewardship initiative on time to administration of empirical antibiotic therapy in hospitalized patients with bacteremia. American Journal of Health-System Pharmacy, 2017, 74, 511-519.	1.0	9
12	Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0204621.	3.2	9
13	Implementation of a \hat{I}^2 -lactam therapeutic drug monitoring program: Experience from a large academic medical center. American Journal of Health-System Pharmacy, 2022, 79, 1586-1591.	1.0	9
14	Incidence of Antiretroviral Drug Interactions During Hospital Course. Journal of Pharmacy Technology, 2014, 30, 48-53.	1.0	7
15	Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion. Microbiology Insights, 2018, 11, 117863611880454.	2.0	7
16	Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (REDUCE-BSI). Antimicrobial Stewardship & Healthcare Epidemiology, 2022, 2, .	0.5	5
17	SCAN: A novel approach for vancomycin time-out. Infection Control and Hospital Epidemiology, 2018, 39, 1501-1503.	1.8	4
18	Applying Cefepime Population Pharmacokinetics to Critically Ill Patients Receiving Continuous Renal Replacement Therapy. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0161121.	3.2	4

#	Article	IF	CITATIONS
19	Use of an Anti-Infective Medication Review Process at Hospital Discharge to Identify Medication Errors and Optimize Therapy. Journal of Pharmacy Practice, 2019, 32, 488-492.	1.0	3
20	Impact of Gastric Acidity on the Acquisition of Cholera Post Gastric Bypass. Bariatric Surgical Patient Care, 2013, 8, 113-116.	0.5	1
21	Impact of supplemental individual verbal defense on confidence, engagement, and performance in a team-based learning therapeutics course. Currents in Pharmacy Teaching and Learning, 2021, 13, 152-158.	1.0	1
22	Impact of an Extended Infusion Î'-lactam Strategy on Outcomes in Critically III Patients with Pseudomonas Infections. Open Forum Infectious Diseases, 2017, 4, S299-S299.	0.9	0
23	2425. Clinical and Microbiologic Outcomes Among Patients With Monomicrobial Stenotrophomonas maltophilia Infections. Open Forum Infectious Diseases, 2018, 5, S725-S725.	0.9	O
24	Resource Over-Utilization in Hospitalized Patients With Uncomplicated Skin and Soft Tissue Infections. Journal of Pharmacy Practice, 2021, , 089719002110002.	1.0	0
25	1576. Re-Evaluation of cefepime or piperacillin-tazobactam to Decrease Use of Carbapenems in ESBL-Producing <i>Enterobacterales</i> BloodStream Infections (REDUCE-BSI). Open Forum Infectious Diseases, 2020, 7, S786-S787.	0.9	0
26	143. Modification of Linezolid Restriction Criteria Reduces ICU Gram-positive Antibiotic Consumption. Open Forum Infectious Diseases, 2020, 7, S201-S202.	0.9	0
27	1575. Predictors of Negative Clinical Outcomes among Patients treated with Meropenem-Vaborbactam for Serious Gram-Negative Bacterial Infections: Impact of Delayed Appropriate Antibiotic Selection. Open Forum Infectious Diseases, 2020, 7, S786-S786.	0.9	0